Skin diseases in consequence of endocrine alterations

Aging Male

Volumn 9, Issue 2, 2006, Pages 81-95

  Krause, Walter ^a,b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Endocrine diseases; Hormonal abnormalities; Skin diseases

Indexed keywords

ACETYLSALICYLIC ACID; ALCLOMETASONE DIPROPIONATE; ANDROGEN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAMETHASONE DIPROPIONATE; BUDESONIDE; CALCIPOTRIOL; CLOBETASOL PROPIONATE; CORTICOSTEROID; ESTROGEN; FINASTERIDE; FLUTICASONE PROPIONATE; GROWTH HORMONE; HORMONE; HYDROCORTISONE 17 BUTYRATE 21 PROPIONATE; HYDROCORTISONE 17,21 ACEPONATE; INSULIN; INTERFERON; METHYLPREDNISOLONE ACEPONATE; MOMETASONE FUROATE; MONOCLONAL ANTIBODY; PREDNICARBATE; PRESERVATIVE; RETINOIC ACID; STRONTIUM 89; TESTOSTERONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D;

ACANTHOSIS NIGRICANS; ADDISON DISEASE; AGING; ALOPECIA; ANALYTICAL EQUIPMENT; ANDROGEN METABOLISM; ARTHRALGIA; ARTICLE; CARCINOID SYNDROME; CARNEY COMPLEX; CARPAL TUNNEL SYNDROME; CORTICOSTEROID METABOLISM; CUSHING DISEASE; DERMATOLOGY; DIABETES MELLITUS; DIABETIC DERMOPATHY; DIABETIC FOOT; DRUG HYPERSENSITIVITY; EDEMA; ENDOCRINE DISEASE; ENDOCRINOLOGY; ESTROGEN DEFICIENCY; ESTROGEN METABOLISM; GENE MUTATION; GENETIC DISORDER; GLUCAGONOMA; GROWTH HORMONE RELEASE; GYNECOMASTIA; HORMONE RELEASE; HUMAN; HYPERINSULINEMIA; HYPOGONADISM; INJECTION SITE REACTION; INTRACRANIAL HYPERTENSION; LEG EDEMA; MERKEL CELL TUMOR; MYALGIA; NECROBIOSIS LIPOIDICA; PAIN; PAPILLEDEMA; PARAPROTEINEMIA; PIGMENT DISORDER; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; SKIN DISEASE; SODIUM RETENTION; TARGET ORGAN; THYROID DISEASE; UNSPECIFIED SIDE EFFECT; URTICARIA; VITAMIN D METABOLISM; VITILIGO; WATER RETENTION; WEIGHT GAIN;

ANDROGENS; ENDOCRINE SYSTEM; ESTROGENS; GLUCAGONOMA; MALIGNANT CARCINOID SYNDROME; SKIN DISEASES; THYROID HORMONES; VITAMIN D; VITILIGO;

EID: 33747777814     PISSN: 13685538     EISSN: 14730790     Source Type: Journal    
DOI: 10.1080/13685530600708573     Document Type: Article

References (71)

1. Grandhe NP, Bhansali A, Dogra S, Kumar B. Acanthosis nigricans: Relation with type 2 diabetes mellitus, anthropometric variables, and body mass in Indians. Postgrad Med J 2005;81(958):541-544.
2. Selkin BA, Reynolds RV, Selkin G. Cutaneous manifestations of internal malignancy. UptoDate® 2005. Available at: http://www.utdol.com
3. Mekhail TM, Markman M. Acanthosis nigricans with endometrial carcinoma: Case report and review of the literature. Gynecol Oncol 2002;84(2):332-334.
4. Torley D, Bellus GA, Munro CS. Genes, growth factors and acanthosis nigricans. Br J Dermatol 2002;147(6):1096-1101.
5. Garcia Hidalgo L. Dermatological complications of obesity. Am J Clin Dermatol 2002;3(7):497-506.
6. McPhaul MJ, Young M. Complexities of androgen action. J Am Acad Dermatol 2001;45(Suppl):S87-S94.
7. Oh BR, Kim SJ, Moon JD, Kim HN, Kwon DD, Won YH, Ryu SB, Park YI. Association of benign prostatic hyperplasia with male pattern baldness. Urology 1998;51(5):744-748.
8. Gruber D, Sator M, Frigo P, Knogler W, Huber JC. Korrelation der Hautfaltendicke mit der Knochendichte, Östradiol, FSH und Prolactinspiegel bci 231 Frauen. Wien Klin Wochenschr 1995;107(20):622-625.
9. Denti L, Pasolini G, Sanfelici L, Benedetti R, Cecchetti A, Ceda GP, Ablondi F, Valenti G. Aging-related decline of gonadal function in healthy men: Correlation with body composition and lipoproteins. J Am Geriatr Soc 2000;48(1):51-58.
10. Hoffmann R. Male androgenetic alopecia. Clin Exp Derm 2002;27:373-382.
11. Kasten R, Pfirrmann G, Voigtlander V. Klinefelter's syndrome associated with mixed connective tissue disease (Sharp's syndrome) and thrombophilia with postthrombotic syndrome. J Dtsch Dermatol Ges 2005;3(8):623-626.
12. Swerdlow AJ, Schoemaker MJ, Higgins CD, Wright AF, Jacobs PA. UK Clinical Cytogenetics Group. Cancer incidence and mortality in men with Klinefelter syndrome: A cohort study. J Natl Cancer Inst 2005;97(16):1204-1210.
13. Hoffmann R. TrichoScan: A novel tool for the analysis of hair growth in vivo. J Investig Dermatol Symp Proc 2003;8(1):109-115.
14. Öberg K. Carcinoid tumors, carcinoid syndrome, and related disorders. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, editors. Williams Textbook of Endocrinology. 10th ed. Philadelphia: Saunders; 2003. pp 1857-1870.
15. Rapaport MJ. Follow-up of 1 mg finasteride treatment of male pattern baldness - difference between clinical trials and private office follow-up: Influences on prescribing habits evaluated. Dermatol Surg 2004;30(5):761-763.
16. Modlin IM, Shapiro MD, Kidd M. An analysis of rare carcinoid tumors: Clarifying these clinical conundrums. World J Surg 2005;29(1):92-101.
17. Bell HK, Poston GJ, Vora J, Wilson NJE. Cutaneous manifestations of the malignant carcinoid syndrome. Br J Dermatol;152:71-75.
18. Sitaraman SV, Goldfinger ST. The carcinoid syndrome. UpToDate (13.2) June 2005. Available at: http://www.utdol. com
19. Freinkel RK, Freinkel N. Cutaneous manifestations of endocrine disorders. In: Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg JM, Austen KF, editors. Dermatology in general medicine. New York: McGraw Hill; 1987. Chapter 174.
20. Stewart PM. The adrenal cortex. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, editors. Williams textbook of endocrinology, 10th ed. Philadelphia: Saunders; 2003. pp 491-551.
21. Ponec M. Hormone receptors in the skin. In: Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg JM, Austen KF, editors. Dermatology in general medicine. New York: McGraw Hill; 1987. Chapter 31.
22. Payne DN, Adcock IM. Molecular mechanisms of corticosteroid actions. Paediatr Respir Rev 2001;2(2):145-150.
23. Rosmond R. The glucocorticoid receptor gene and its association to metabolic syndrome. Obes Res 2002;10(10):1078-1086.
24. Brazzini B, Pimpinelli N. New and established topical corticosteroids in dermatology: Clinical pharmacology and therapeutic use. Am J Clin Dermatol 2002;3(1):47-58.
25. Wozniak KD, Bar M. Zur bedeutung von hautveränderungen beim diabetes mellitus. Z Gesamte Inn Med 1990;45(22):669-673.
26. Richardson T, Kerr D. Skin-related complications of insulin therapy: Epidemiology and emerging management strategies. Am J Clin Dermatol 2003;4(10):661-667.
27. Greenman RL, Panasyuk S, Wang X, Lyons TE, Dinh T, Longoria L, Giurini JM, Freeman J, Khaodhiar L, Veves A. Early changes in the skin microcirculation and muscle metabolism of the diabetic foot. Lancet 2005;366(9498):1711-1717.
28. Freinkel RK, Freinkel N. Cutaneous manifestations of endocrine disorders. In: Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg JM, Austen KF, editors. Dermatology in general medicine. New York: McGraw Hill; 1987. Chapter 174.
29. Pinzur M, Freeland R, Juknelis D. The association between body mass index and foot disorders in diabetic patients. Foot Ankle Int 2005;26(5):375-377.
30. Mendonca DA, Cosker T, Makwana NK. Vacuum-assisted closure to aid wound healing in foot and ankle surgery. Foot Ankle Int 2005;26(9):761-766.
31. Tom WL, Peng DH, Allaei A, Hsu D, Hata TR. The effect of short-contact topical tretinoin therapy for foot ulcers in patients with diabetes. Arch Dermatol 2005;141(11):1373-1377.
32. Brownlee M, Aiello LP, Friedman E, Vinik AI, Nesto RW, Boulton JM. Complications of diabetes mellitus. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, editors. Williams textbook of endocrinology, 10th ed. Philadelphia: Saunders; 2003. pp 1509-1584.
33. Frykberg RG. An evidence-based approach to diabetic foot infections. Am J Surg 2003;186(5A):S44-S54.
34. Robbins JM. Treatment of onychomycosis in the diabetic patient population. J Diabetes Complications 2003;17(2):98-104.
35. McCulloch DK. Evaluation of the diabetic foot. UptoDate® 2005. Available at: http://www.utdol.com
36. Chuang TY, Lewis DA, Spandau DF. Decreased incidence of nonmelanoma skin cancer in patients with type 2 diabetes mellitus using insulin: A pilot study. Br J Dermatol 2005;153(3):552-557.
37. Raine-Fenning NJ, Brincat MP, Muscat-Baron Y. Skin aging and menopause: Implications for treatment. Am J Clin Dermatol 2003;4(6):371-378.
38. Wildt L, Sir-Peterman T. Oestrogen and age estimations of perimenopausal women. Lancet 1999;354:224.
39. Niewöhner CB, Nuttall RQ. Gynecomastia in a hospitalized male population. Amer J Med 1984;77:633-638.
40. Carney JA, Hruska LS, Beauchamp GD, Gordon H. Dominant inheritance of the complex of myxomas, spotty pigmentation, and endocrine overactivity. Mayo Clin Proc 1986;61(3):165-172.
41. Carney, JA. Carney complex: The complex of myxomas, spotty pigmentation, endocrine overactivity and schwannomas. Semin Dermatol 1995;14:90.
42. Nieman LK. Cushing's syndrome due to ACTH-independent micronodular and macronodular adrenal hyperplasia. Available at: UpToDate Version 13.3, September 8, 2004.
43. Kyle RA. POEMS syndrome (osteosclerotic myeloma). Available at: UpToDate September 12, 2005.
44. Dispenzieri A, Kyle RA, Lacy MQ, et al. POEMS syndrome. Definitions and long-term outcome. Blood 2003;101:2496.
45. Perniciaro C. POEMS syndrome. Semin Dermatol 1995;14:162.
46. Rosenberg PM, Goldfinger ST. Glucagonoma and the glucagonoma syndrome. UptoDate® 2005. Available at: http://www.utdol.com
47. van Beek AP, de Haas ER, van Vloten WA, Lips CJ, Roijers JF, Canninga-van Dijk MR. The glucagonoma syndrome and necrolytic migratory erythema: A clinical review. Eur J Endocrinol 2004;151(5):531-537.
48. Chastain MA. The glucagonoma syndrome: A review of its features and discussion of new perspectives. Am J Med Sci 2001;321(5):306-320.
49. Zhang M, Xu X, Shen Y, Hu ZH, Wu LM, Zheng SS. Clinical experience in diagnosis and treatment of glucagonoma syndrome. Hepatobiliary Pancreat Dis Int 2004;3(3):473-475.
50. Quatresooz P, Hermanns-Le T, Ciccarelli A, Beckers A, Pierard GE. Tensegrity and type 1 dermal dendrocytes in acromegaly. Eur J Clin Invest 2005;35(2):133-139.
51. LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003;195(2):127-137.
52. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: Systematic review and meta-regression analysis. Lancet 2004;363(9418):1346-1353.
53. Carroll PV, Christ ER, Bengtsson BA, Carlsson L, Christiansen JS, Clemmons D, Hintz R, Ho K, Laron Z, Sizonenko P, et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: A review. Growth Hormone Research Society Scientific Committee. J Clin Endocrinol Metab 1998;83(2):382-395.
54. Pinkus 1902 (cited in Moll et al., 2005).
55. Moll I, Roessler M, Brandner JM, Eispert AC, Houdek P, Moll R. Human Merkel cells - aspects of cell biology, distribution and functions. Eur J Cell Biol 2005;84(2-3):259-271.
56. Koljonen V, Haglund C, Tukiainen E, Bohling T. Neuroendocrine differentiation in primary Merkel cell carcinoma - possible prognostic significance. Anticancer Res 2005;25(2A):853-858.
57. Larsen PR, Davies TF, Schlumberger MJ, Hay ID. Thyroid physiology and diagnostic evalulation of patients with thyroid disorders. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, editors. Williams textbook of endocrinology. 10th ed. Philadelphia: Saunders; 2003. pp 33-37.
58. O'Donnell BF, Francis DM, Swana GT, Seed PT, Kobza Black A, Greaves MW. Thyroid autoimmunity in chronic urticaria. Br J Dermatol 2005;153(2):331-335.
59. Fatourechi V. Pretibial myxedema: Pathophysiology and treatment options. Am J Clin Dermatol 2005;6(5):295-309.
60. Davies TF, Larsen RP. Thyrotoxicos. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, editors. Williams textbook of endocrinology. 10th ed. Philadelphia: Saunders; 2003. pp 374-422.
61. Stumpf WE. The endocrinology of sunlight and darkness. Complementary roles of vitamin D and pineal hormones. Naturwissenschaften 1988;75(5):247-251.
62. Scarlett WL. Ultraviolet radiation: Sun exposure, tanning beds, and vitamin D levels. What you need to know and how to decrease the risk of skin cancer. J Am Osteopath Assoc 2003;103(8):371-375.
63. Bollinger Bollag W, Bollag RJ. 1,25-Dihydroxyvitamin D(3), phospholipase D and protein kinase C in keratinocyte differentiation. Mol Cell Endocrinol 2001;177(1-2):173-182.
64. Kira M, Kobayashi T, Yoshikawa K. Vitamin D and the skin. J Dermatol 2003;30(6):429-437.
65. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004;80(6 Suppl):S1678-S88.
66. Njoo MD, Westerhof W. Vitiligo. Pathogenesis and treatment. Am J Clin Dermatol 2001;2(3):167-181.
67. Huang CL, Nordlund JJ, Boissy R. Vitiligo: A manifestation of apoptosis? Am J Clin Dermatol 2002;3(5):301-308.
68. Kadekaro AL, Kanto H, Kavanagh R, Abdel-Malek ZA. Significance of the melanocortin 1 receptor in regulating human melanocyte pigmentation, proliferation, and survival. Ann NY Acad Sci 2003;994:359-365.
69. Wankowicz-Kalinska A, Le Poole C, van den Wijngaard R, Storkus WJ, Das PK. Melanocyte-specific immune response in melanoma and vitiligo: Two faces of the same coin? Pigment Cell Res 2003;16(3):254-260.
70. Luger TA, Schwarz T, Kalden H, Scholzen T, Schwarz A, Brzoska T. Role of epidermal cell-derived α melanocyte stimulating hormone in ultraviolet light mediated local immunosuppression. Ann NY Acad Sci 1999;20;885:209-216.
71. Luger TA, Scholzen TE, Brzoska T, Bohm M. New insights into the functions of α-MSH and related peptides in the immune system. Ann NY Acad Sci 2003;994:133-140.